Savant Capital LLC Sells 3,623 Shares of Bristol-Myers Squibb (NYSE:BMY)

Savant Capital LLC trimmed its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 7.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,037 shares of the biopharmaceutical company’s stock after selling 3,623 shares during the quarter. Savant Capital LLC’s holdings in Bristol-Myers Squibb were worth $2,311,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. MONECO Advisors LLC lifted its position in Bristol-Myers Squibb by 34.6% in the 4th quarter. MONECO Advisors LLC now owns 9,689 shares of the biopharmaceutical company’s stock valued at $497,000 after acquiring an additional 2,490 shares in the last quarter. Northcape Wealth Management LLC lifted its position in Bristol-Myers Squibb by 6.4% in the 4th quarter. Northcape Wealth Management LLC now owns 6,684 shares of the biopharmaceutical company’s stock valued at $343,000 after acquiring an additional 402 shares in the last quarter. Vanguard Capital Wealth Advisors lifted its position in Bristol-Myers Squibb by 107.5% in the 4th quarter. Vanguard Capital Wealth Advisors now owns 8,300 shares of the biopharmaceutical company’s stock valued at $426,000 after acquiring an additional 4,300 shares in the last quarter. Certuity LLC lifted its position in Bristol-Myers Squibb by 55.9% in the 4th quarter. Certuity LLC now owns 40,729 shares of the biopharmaceutical company’s stock valued at $2,090,000 after acquiring an additional 14,606 shares in the last quarter. Finally, Norden Group LLC lifted its position in Bristol-Myers Squibb by 7.8% in the 4th quarter. Norden Group LLC now owns 10,633 shares of the biopharmaceutical company’s stock valued at $546,000 after acquiring an additional 773 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Stock Down 1.2 %

Shares of BMY opened at $43.70 on Friday. Bristol-Myers Squibb has a 52 week low of $43.33 and a 52 week high of $69.10. The firm has a market cap of $88.58 billion, a P/E ratio of -14.10, a price-to-earnings-growth ratio of 14.70 and a beta of 0.45. The firm’s 50-day simple moving average is $50.52 and its 200 day simple moving average is $50.84. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same quarter in the prior year, the business posted $2.05 EPS. The business’s revenue was up 4.7% compared to the same quarter last year. On average, analysts forecast that Bristol-Myers Squibb will post 0.6 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.49%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Wall Street Analysts Forecast Growth

BMY has been the topic of several research reports. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Barclays cut their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. BMO Capital Markets cut their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Redburn Atlantic cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price target for the stock from $77.00 to $54.00 in a research report on Tuesday, February 6th. Finally, StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $60.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.